<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen Mowry, MD, MCR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults.</p><p>The initial treatment of relapsing-remitting multiple sclerosis (RRMS) with disease-modifying therapies (DMTs) is reviewed here. Switching DMT because of ineffectiveness, intolerance, or other reasons is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis"</a>.)</p><p>The treatment of progressive forms of MS is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p>Other aspects of MS are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">Overview of disease-modifying therapies for multiple sclerosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/143125.html" rel="external">Clinical use of oral disease-modifying therapies for multiple sclerosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/96016.html" rel="external">Pathogenesis and epidemiology of multiple sclerosis</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">Clinical presentation, course, and prognosis of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">Evaluation and diagnosis of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">Manifestations of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">Symptom management of multiple sclerosis in adults</a></p><p class="bulletIndent1"><span class="glyph">●</span> <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">Evaluation and diagnosis of multiple sclerosis in adults</a></p><p></p><p class="headingAnchor" id="H2563518811"><span class="h1">PATTERN AND COURSE OF MS</span><span class="headingEndMark"> — </span>MS is categorized into several clinical subtypes, as reviewed here briefly and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Disease onset and pattern'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>A clinically isolated syndrome (CIS) is the first clinical episode that is consistent with a demyelinating etiology and is suggestive of MS. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Clinically isolated syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A radiologically isolated syndrome (RIS) is defined by incidental brain or spinal cord magnetic resonance imaging (MRI) findings that are highly suggestive of MS, based upon location and morphology within the central nervous system, in an asymptomatic patient lacking any history, symptoms, or signs of MS. (See  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis", section on 'Radiologically isolated syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapsing-remitting multiple sclerosis (RRMS) is characterized by clearly defined relapses with either full recovery, or with sequelae and residual deficit upon recovery. There is no or minimal disease progression during the periods between disease relapses, though individual relapses themselves may result in severe residual disability. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Relapsing-remitting MS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary progressive multiple sclerosis (SPMS) begins as relapsing-remitting disease, but over time the disease enters a stage of steady deterioration in function, with or without superimposed attacks, hence the designation of "secondary." Secondary progressive disease is the single largest category of MS. Typically, when the secondary progressive stage is reached, the relapse rate is also reduced. This type of MS, which ultimately develops in up to 90 percent of untreated patients with RRMS after 25 years, causes the greatest amount of neurologic disability attributable to MS. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Secondary progressive MS'</a>.)</p><p></p><p class="bulletIndent1">SPMS can be further characterized at different points in time as either active (with relapses and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapses) or without progression. Disease-modifying therapy (DMT) is available for active secondary progressive MS. (See  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary progressive multiple sclerosis (PPMS) represents approximately 10 percent of MS cases and is characterized by disease progression from onset, although occasional plateaus, temporary minor improvements, and acute relapses may occur. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Primary progressive MS'</a>.)</p><p></p><p class="bulletIndent1">PPMS can also be characterized at different points in time as either active (with a relapse and/or evidence of MRI activity) or not active, as well as with or without progression. DMT for primary progressive MS is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1516417816"><span class="h1">DMT INDICATIONS, TIMING, AND GOALS</span></p><p class="headingAnchor" id="H1326550470"><span class="h2">Who should be treated?</span><span class="headingEndMark"> — </span>Everyone with a diagnosis of clinically definite relapsing-remitting multiple sclerosis (RRMS) should be offered disease-modifying therapy (DMT) [<a href="#rid1">1-3</a>]. DMTs are described briefly here and reviewed in detail separately. There is considerable evidence that earlier treatment is associated with a better long-term outcome [<a href="#rid4">4-9</a>]. (See  <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis"</a>.)</p><p>DMTs have also shown benefit for selected patients with a clinically isolated syndrome (CIS), secondary progressive multiple sclerosis (SPMS), or primary progressive multiple sclerosis (PPMS), as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a CIS or RIS suggestive of MS who do not completely meet McDonald criteria for MS but have additional clinically silent lesions in the brain or spinal cord detected by magnetic resonance imaging (MRI) (see  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who reach the stage of SPMS and have active disease, as determined by ongoing clinical relapses and/or new MS lesions on MRI (see  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with PPMS who are younger (eg, age ≤55 years) or have active disease on MRI (see  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>)</p><p></p><p class="headingAnchor" id="H4174733949"><span class="h2">Importance of early treatment</span><span class="headingEndMark"> — </span>We start DMT as soon as possible for all patients with RRMS. Accumulating data from observational studies suggest that the use of DMT is associated with a lower long-term risk of MS disease progression [<a href="#rid4">4-10</a>], which may be enabled more with the early use of the high-efficacy monoclonal antibody DMTs (eg, <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>) [<a href="#rid11">11,12</a>]. As an example, an observational cohort study analyzed data for over 1500 propensity-matched patients with RRMS and a minimum follow-up period of four years who were untreated or treated with interferon beta, <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>, <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, natalizumab, or alemtuzumab [<a href="#rid6">6</a>]. Initial treatment with each of these DMTs was associated with a lower risk of conversion to secondary progressive MS compared with no DMT treatment; the risk was lower for early initial DMT (within five years of disease onset) compared with later treatment. Furthermore, the associated risk of conversion was lower for initial treatment with fingolimod, alemtuzumab, or natalizumab compared with initial treatment with glatiramer acetate or interferon beta (hazard ratio 0.66, 95% CI 0.44-0.99, five-year absolute risk 7 percent [16 of 235] versus 12 percent [46 of 380]. One limitation to this study is that relatively few patients contributed to each of the individual comparisons, and patients using various treatment strategies often came from different time periods and countries. Another is that techniques such as propensity scores cannot fully account for unmeasured confounders.</p><p class="headingAnchor" id="H1621573795"><span class="h2">Treatment goals</span><span class="headingEndMark"> — </span>The primary treatment goals of DMT are preventing MS relapses (attacks), reducing the accumulation of neurologic impairment and disability over time, and reducing brain inflammation and injury [<a href="#rid13">13</a>]. Accumulating data suggest that DMTs reduce disability progression in adult and pediatric patients with RRMS, at least in the short term (eg, two to three years) [<a href="#rid14">14-16</a>].</p><p>However, it is not yet established whether these medications reduce long-term disability, and whether they do so differentially. In an effort to address the long-term effect on DMTs on disability, an analysis of observational data from the MSBase registry compared worsening and improvement of disability and the incidence of relapses during periods of DMT treatment versus no treatment [<a href="#rid17">17</a>]. For 1085 patients with RRMS and 15 or more years of follow-up, 1061 of whom used injectable therapies, treated patients were less likely to experience relapses (hazard ratio [HR] 0.59, 95% CI 0.50-0.70) and worsening of disability (HR 0.81, 95% CI 0.67-0.99). The novel methodology used for the study considered every three-month epoch as on-treatment or off-treatment. However, this may be difficult to apply to people with MS, since immune-modulating medications may take longer than three months to gain effectiveness when started, and similarly may take longer than three months to lose effectiveness when stopped. Further studies are needed to confirm whether DMTs lower the risk of long-term disability.</p><p class="headingAnchor" id="H290631704"><span class="h1">CATEGORIES OF DMT</span><span class="headingEndMark"> — </span>A number of immunomodulatory agents have important beneficial effects for patients with RRMS, mainly a decreased relapse rate and a slower accumulation of brain lesions on MRI. These DMTs for MS can be grouped by method of administration into infusion, oral, and injectable drugs.</p><p class="headingAnchor" id="H4136421603"><span class="h2">Monoclonal antibodies</span><span class="headingEndMark"> — </span>Monoclonal antibodies for MS include <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="140396" href="/z/d/drug information/140396.html" rel="external">ublituximab</a>, and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>. These DMTs may be preferred for patients with more active disease and for those who place a high value on efficacy and are risk-tolerant. However, serious safety issues, including infections, are possible adverse effects of several of these medications. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H2795931817"><span class="h2">Oral therapies</span><span class="headingEndMark"> — </span>Oral therapies for MS include the fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), sphingosine 1-phosphate receptor (S1PR) modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>), <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>, and <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>. These oral DMTs may be preferred for patients who value a self-administered oral medication over medications requiring injections and infusions. (See  <a class="medical medical_review" href="/z/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H2655330359"><span class="h2">Platform injection therapies</span><span class="headingEndMark"> — </span>Older injectable (intramuscular and subcutaneous) forms of DMT for MS include <a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">recombinant human interferon beta-1b</a>, <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a>, and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>. The interferons and glatiramer acetate were the first DMTs approved for MS and are sometimes called the "platform" therapies for this reason. These older DMTs may be preferred for patients who value safety and are less concerned about convenience or achieving the highest effectiveness. (See  <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis", section on 'Platform therapies'</a>.)</p><p class="headingAnchor" id="H2502924384"><span class="h2">Comparative efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence</strong> – The available evidence, based upon a limited number of randomized controlled trials, indirect cross-trial comparisons, observational studies, and clinical experience, suggests that the monoclonal antibodies (<a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>) and (possibly) <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> have the highest efficacy; S1PR modulators (eg, <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>) and fumarates (eg, <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>) have an intermediate efficacy; and <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> and the older platform DMTs (interferons and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>) have the lowest efficacy [<a href="#rid18">18-30</a>]. However, it is uncertain how closely DMT efficacy inferred from clinical studies correlates with effectiveness in the "real world," where the populations and related treatment decisions differ from the scenarios in trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Populations studied</strong> – Note that clinical trials of DMTs in MS have been performed in many regions and populations but have mainly involved individuals of White European ancestry. In some countries, areas, and situations, this racial construct may not reflect the composition of the population being treated. Treatment decisions should therefore be individualized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit for individual patients</strong> – Clinicians should tell patients that the relative additional benefit of highly effective DMTs comes from comparisons of their average ability to reduce relapses and new MS lesions on MRI in large groups. However, the average benefit of a DMT may not apply to an individual patient; that person may be much more likely, or much less likely, to respond to a given agent. None of the DMTs constitute a cure; they are only partially effective for reducing the relapse rate, and whether all or any reduce long-term disability progression is still under active investigation.</p><p></p><p class="headingAnchor" id="H1473718041"><span class="h1">FACTORS INFLUENCING THE CHOICE OF DMT</span><span class="headingEndMark"> — </span>A number of issues may help to guide DMT options for individual patients [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1281535081"><span class="h2">Assessment for risk of MS worsening</span><span class="headingEndMark"> — </span>The risk of future disease activity (ie, a relapse or new T2 or enhancing lesions on brain MRI within the next two years) in patients with RRMS can help guide the choice of DMT. Clinicians should assess patients with RRMS at presentation and periodically thereafter for features associated with a poor prognosis and higher risk of future relapse and severe disability [<a href="#rid3">3</a>]. These include the following [<a href="#rid3">3,13,31-38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Demographic:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Onset of MS after age 30, even though the risk of relapse paradoxically decreases with age</p><p class="bulletIndent2"><span class="glyph">•</span>Motor or cerebellar onset</p><p class="bulletIndent2"><span class="glyph">•</span>Male sex</p><p class="bulletIndent2"><span class="glyph">•</span>Americans of Black, Asian, or Hispanic ethnicity</p><p class="bulletIndent2"><span class="glyph">•</span>Former or current smoking</p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid cardiovascular disease</p><p class="bulletIndent2"><span class="glyph">•</span>Obesity</p><p class="bulletIndent2"><span class="glyph">•</span>Sedentary lifestyle</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor relapse recovery</p><p class="bulletIndent2"><span class="glyph">•</span>Frequent early attacks</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of oligoclonal bands in the cerebrospinal fluid</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiologic:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High burden of disease by T2 lesion volume on MRI</p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing disease activity by enhancing or new T2 lesions on MRI</p><p class="bulletIndent2"><span class="glyph">•</span>Spinal cord lesion(s)</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of brain atrophy</p><p></p><p>Of these, the most important factors predicting a worse clinical course and poor long-term outcome are the presence of highly active disease (eg, frequent relapses and new MRI lesions), extensive radiologic involvement of MS lesions (eg, multifocal lesions, high lesion number; and high T2 burden of disease), spinal cord involvement, and/or poor relapse recovery [<a href="#rid3">3</a>]. Patients with these characteristics may be good candidates for starting treatment with highly effective DMT. (See <a class="local">'Starting with high efficacy therapy'</a> below.)</p><p>However, prognostic studies are often limited because few have examined all factors concomitantly in representative populations (eg, Black patients have often been underrepresented in these cohorts, which tend to enroll predominantly White patients from Europe).</p><p class="headingAnchor" id="H2413420926"><span class="h2">Shared decision-making</span><span class="headingEndMark"> — </span>Shared decision-making incorporates the patient's values and preferences into medical decisions and puts the patient at the center of care.</p><p>Patient values and preferences include individual patient views about drug efficacy, safety, tolerability (with a goal of minimizing risks and side effects), and convenience; willingness to perform injections, readiness to start DMT, urgency to start DMT, and likelihood of adherence.</p><p>The patient, clinician, and care team should jointly consider the decision to start a DMT and select the best option, evaluating the evidence, benefits, risks, and burdens of the available DMTs [<a href="#rid13">13,39</a>]. Important aspects include patient education about the natural history of MS, the patient's prognostic factors, the DMT categories and differentiating factors, the treatment goals, and the expected treatment outcomes. Decision aids (eg, text, audio-visual material, interactive media) about MS and the role of DMT may also be helpful.</p><p>This process takes time. Experts generally advise that providing a second, close follow-up appointment after the appointment at which the diagnosis is confirmed and the DMT options are presented. This allows newly diagnosed patients the opportunity to review the diagnosis and consider therapies and questions they have about them before committing to a specific therapy. Laboratory testing ordered at the first visit helps inform the relative safety of some DMTs, and the test results can be incorporated into the discussion at the follow-up appointment.</p><p>Shared decision making has been associated in some studies with improvements in disease knowledge, satisfaction with care, treatment adherence, health outcomes, and health-related quality of life [<a href="#rid13">13,39-41</a>].</p><p class="headingAnchor" id="H2239740493"><span class="h2">Women of childbearing potential</span><span class="headingEndMark"> — </span>Women with MS are typically at childbearing potential for most of the relapsing-remitting phase of the disease. Women of childbearing potential may wish to avoid starting DMTs that are confirmed or possible teratogens (eg, <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>), or that may be associated with greater risk of rebound on discontinuation (<a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, fingolimod, and, presumably, siponimod and ozanimod) if they are planning pregnancy soon or are unwilling to use highly effective contraceptive strategies. Other DMTs have uncertain risks during pregnancy and breastfeeding. These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a> and  <a class="medical medical_review" href="/z/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p class="headingAnchor" id="H2697954787"><span class="h2">Drug availability</span><span class="headingEndMark"> — </span>The availability of some DMTs may be limited due to geographic distribution, national regulations, cost and financial limitations, and insurance restrictions.</p><p class="headingAnchor" id="H2955116512"><span class="h1">SELECTING INITIAL DMT</span><span class="headingEndMark"> — </span>There is no uniform method for selecting initial disease-modifying therapy (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS). Two broad treatment paradigms are advocated by different experts: starting with highly effective therapy or starting with low-risk therapy. In addition, some experts and patients prefer to start with oral therapy, which is (on average) intermediate for efficacy and risk.</p><p class="headingAnchor" id="H1394161517"><span class="h2">Starting with high efficacy therapy</span><span class="headingEndMark"> — </span>An approach favored by some experts is to start most patient with RRMS using one of the high-efficacy DMTs, such as <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, and <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>. The main advantage of this approach is the relatively high efficacy of these DMTs, given natural history data for MS, which suggest that relapses and new magnetic resonance imaging (MRI) changes are most frequent at the onset of MS [<a href="#rid42">42</a>], a time when patients are youngest and when DMTs may be most effective and tolerable [<a href="#rid21">21</a>]. </p><p>The main disadvantage of this approach is the risk of severe adverse events with these therapies; this includes the risk of serious infections (eg, the risk of progressive multifocal leukoencephalopathy [PML] with <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, the potential risk of developing severe coronavirus disease 2019 [COVID-19] (see <a class="local">'COVID-19'</a> below), and the potential impact on COVID-19 vaccine effectiveness) and the risk of breakthrough disease associated with natalizumab withdrawal. The burden and inconvenience of periodic infusions or injections is another disadvantage of some of these DMTs.</p><p>Because of their safety profile, some high-efficacy DMTs (eg, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>) are usually reserved for patients who do not tolerate or have an inadequate response to other drugs for MS.</p><p class="headingAnchor" id="H991673496"><span class="h2">Starting with low-risk therapy (escalation approach)</span><span class="headingEndMark"> — </span>Another approach favored by some experts is to start treatment using older injectable DMTs (beta interferons and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>) for patients with RRMS, particularly for those with a minimal disease burden or who are risk averse. Escalation to intermediate efficacy oral DMT or high efficacy infusion DMT is then implemented only for patients who develop new MS attacks or evidence of new lesions on brain MRI [<a href="#rid21">21</a>]. </p><p>The main advantage of this approach is that the older injectable DMTs have long-term evidence of safety; serious adverse events are rare. The main disadvantages are the relatively modest efficacy of the older injectable DMTs (see <a class="local">'Comparative efficacy'</a> above) and the burden and inconvenience of administration by injection. Some authors point out that most patients who start with platform DMTs will eventually switch (for various reasons) to more effective DMTs; additionally, starting patents on less effective DMTs may risk greater disability over time [<a href="#rid21">21,43</a>].</p><p class="headingAnchor" id="H3675361665"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>For patients with RRMS, we recommend DMT and typically start with one of the agents listed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher effectiveness DMTs</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate effectiveness DMTs</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Oral fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, or <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Oral sphingosine 1-phosphate receptor (S1PR) modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, or <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower effectiveness DMTs</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a></p><p class="bulletIndent2"><span class="glyph">•</span>Intramuscular <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous pegylated <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous <a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">recombinant human interferon beta-1b</a></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a></p><p></p><p>In choosing among these and other available DMTs, clinicians should incorporate individual patient prognostic factors, values and preferences, and drug-related factors (adverse effect profile, cost, availability, and burden of administration), using a shared decision-making process (see <a class="local">'Shared decision-making'</a> above) to optimize choices for individual patients. Ideally, the goal is to try to match the patient's disease severity with the most appropriate DMT; a patient with severe disease with ongoing risk of activity should often be on a more efficacious DMT, while a patient with mild disease should often be on a safe and tolerable DMT. Most of the medications are relatively easy to discontinue if patients are unable to tolerate them or there is breakthrough disease, lowering the pressure to "get it right" the first time.</p><p>The following are reasonable options for choosing initial DMT  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with highly active disease and for patients who place a high value on efficacy and are relatively risk-tolerant, start with highly effective therapy using intravenous <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> or anti-CD20 therapy. With natalizumab therapy, the risk of progressive multifocal leukoencephalopathy increases with the duration of treatment, particularly for those who demonstrate JC virus seropositivity. <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> is also highly effective but is usually reserved for patients who have had an inadequate response to one or more DMTs for RRMS because of its safety profile. Oral <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> is often considered high efficacy but is typically reserved for patients who have had breakthrough disease while on another DMT or are intolerant of other DMTs for MS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with less active disease and for patients who value convenience using a self-administered oral medication compared with medications requiring injections or infusions, start with an oral DMT such as a fumarate or an S1PR modulator. However, serious safety issues (including infections) are possible adverse effects of these medications; clinicians must monitor laboratory tests and other factors related to the adverse effects of these agents, particularly if severe lymphopenia occurs. Of the oral therapies, many patients choose fumarates due to their seemingly better safety profile compared with the S1PR modulators, but practices vary widely [<a href="#rid44">44-46</a>]. The potential teratogenicity of <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> and <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> limit their use for a disease where a substantial portion of patients are of childbearing potential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who place the highest value on safety and are willing to accept lower effectiveness, start with one of the beta interferons or glatiramer.</p><p></p><p class="headingAnchor" id="H2419746616"><span class="h1">IMPLEMENTATION</span></p><p class="headingAnchor" id="H3443475053"><span class="h2">Baseline assessments</span><span class="headingEndMark"> — </span>Most DMTs require baseline and periodic monitoring of clinical parameters (eg, blood pressure) and laboratory tests such a complete blood cell count with lymphocytes, liver function testing, and urinalysis [<a href="#rid3">3,13</a>]. Additional testing is required for certain DMTs, such as screening for the JC virus in patients on <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> or for hepatitis B prior to anti-CD20 therapy. Some experts advise a pregnancy test for women of childbearing potential before starting DMT and prior to some infusions. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H1555809729"><span class="h2">Immunizations</span><span class="headingEndMark"> — </span>Before starting DMT, immunization status should be reviewed and updated according to local and national recommendations [<a href="#rid3">3,13</a>]. Patients should also be screened for immunity to varicella zoster virus and hepatitis A, B, and C, and vaccinated against these viruses as indicated or available. Some DMTs (eg, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>) require that patients receive the last dose of all necessary vaccinations (including, potentially those against severe acute respiratory syndrome coronavirus 2 [SARS CoV-2]) at least four weeks before starting treatment for live or live-attenuated vaccines, and at least two weeks before starting treatment for non-live vaccines. Extending this principle to all anti-B cell therapies (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, bioequivalents) is prudent, considering the anti-CD20 therapies attenuate vaccine responsiveness. However, it is not always feasible or safe to wait; some multi-part vaccines (eg, hepatitis B) could delay treatment start by months, which is unacceptable for patients with ongoing risk of disease activity.</p><p class="headingAnchor" id="H2980259390"><span class="h2">COVID-19</span><span class="headingEndMark"> — </span>We advise coronavirus disease 2019 (COVID-19) vaccination for all patients with MS, in accordance with local availability and allocation priorities. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p>Guidance on the use of DMTs in patients with MS at risk for COVID-19 is provided separately. (See  <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis", section on 'COVID-19 and DMTs'</a>.)</p><p>The management of COVID-19 is discussed in several UpToDate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/128349.html" rel="external">"COVID-19: Management in nursing homes"</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="headingAnchor" id="H835201149"><span class="h2">Monitoring response to therapy</span><span class="headingEndMark"> — </span>The response to disease-modifying therapy (DMT) can be monitored by clinical follow-up with careful attention to possible manifestations of MS disease activity including acute attacks (relapses), development of new MS lesions (particularly more than one) on brain magnetic resonance imaging (MRI), and possibly the onset or progression of sustained disability (the latter needs confirmation) [<a href="#rid1">1,2</a>]. Since DMTs are only partially effective, many MS experts recommend more aggressive treatment when new lesions develop on MRI when the patient is on a specific treatment for six months or more, which is thought to be enough time for DMT to take effect, even when the patient appears to be doing well clinically. (See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis", section on 'Breakthrough or refractory disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periodic MRI</strong> – We supplement the clinical information with periodic neuroimaging (eg, MRI) studies to monitor the development of new asymptomatic MS lesions. MRI imaging also serves to screen asymptomatic patients for lesions suggestive of serious complications (eg, infectious, inflammatory, cerebrovascular) of DMTs [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">In agreement with a consensus guideline, we obtain a brain MRI before starting or switching DMT, another approximately three to six months later, and annually thereafter [<a href="#rid48">48</a>]. More frequent neuroimaging may be desirable for some patients, but is impractical due to financial constraints. Note that the value of screening MRIs likely declines over time in patients on higher-efficacy therapy, and there is debate in the field as to whether even annual imaging is needed in people on these medications. Less frequent imaging may be reasonable for individuals with years of clinically and radiologically stable disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of gadolinium contrast</strong> – Guidelines recommend limiting the use of MRI with gadolinium contrast to selected clinical scenarios [<a href="#rid48">48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When detection or confirmation of recent (ie, within one year) clinical disease activity will influence treatment decisions, such as starting or escalating therapy</p><p class="bulletIndent2"><span class="glyph">•</span>When a recent comparable MRI scan is not available</p><p class="bulletIndent2"><span class="glyph">•</span>When assessment of new MRI disease activity is difficult due to a high baseline T2 lesion burden</p><p></p><p class="bulletIndent1">Repeated contrast-enhanced MRI studies can lead to gadolinium accumulation in brain tissues [<a href="#rid49">49-53</a>]. Although there are no documented adverse effects of such accumulation, it is prudent to carefully reflect on whether gadolinium is needed with each MRI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EDSS</strong> – In addition to MRI, some experts assess patients with the Expanded Disability Status Scale (EDSS)  (<a class="graphic graphic_table graphicRef57639" href="/z/d/graphic/57639.html" rel="external">table 1</a>) every three months, but it is uncertain if change in EDSS alone is an indication to switch therapy in the absence of clinical relapse or MRI evidence of MS disease activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom management</strong> – A range of symptomatic problems can occur in patients with MS. Cognitive dysfunction, depression, fatigue, and mood swings are increasingly common with disease progression. Paroxysmal symptoms, spasticity, tremor, seizures, sphincter dysfunction, and sexual dysfunction may also complicate disease progression. The management of these issues is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute attacks</strong> – Acute attacks (relapses) of MS are typically treated with glucocorticoids, which accelerate recovery. Indications for treatment of a relapse include functionally disabling symptoms with objective evidence of neurologic impairment. This is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2983267842"><span class="h2">Duration of treatment</span><span class="headingEndMark"> — </span>Most disease-modifying therapies (DMTs) are continued indefinitely in clinically stable patients with relapsing-remitting multiple sclerosis (RRMS) unless side effects are intolerable or safety concerns arise [<a href="#rid1">1,2</a>]. However, it may be reasonable to discuss stopping DMT for older patients who have had no new relapses or magnetic resonance imaging (MRI) changes for a prolonged period. This issue is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis", section on 'Reasons for stopping DMT'</a>.)</p><p>For women who desire to become pregnant (or theoretically for men who are using <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>), the risk of possible adverse effects of DMTs on the fetus must be weighed against DMT discontinuation and increased risk of maternal disease relapses. Rebound of MS activity may occur after discontinuing certain DMTs, particularly <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, and, in some case reports, teriflunomide and <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>. These factors must be considered when counseling a woman who wishes to conceive, ideally in consultation with an MS specialist and maternal-fetal medicine specialist. (See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H2202433586"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H18934119"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15821.html" rel="external">"Patient education: Multiple sclerosis in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of disease-modifying therapy (DMT)</strong> – A number of immunomodulatory agents have important beneficial effects for patients with relapsing-remitting multiple sclerosis (RRMS), mainly a decreased relapse rate and a slower accumulation of brain lesions on magnetic resonance imaging (MRI). These disease-modifying therapies (DMTs) for multiple sclerosis (MS) are available as monoclonal antibodies, oral therapies, and older (platform) injectable drugs. (See <a class="local">'Categories of DMT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparative efficacy of DMTs</strong> – The available evidence suggests that several monoclonal antibodies (<a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="140396" href="/z/d/drug information/140396.html" rel="external">ublituximab</a>, and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>) and an oral DMT (<a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>) have the highest efficacy, while oral sphingosine 1-phosphate receptor (S1PR) modulators (eg, <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>) and oral fumarates (eg, <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>) have an intermediate efficacy, and oral <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> and the older injection DMTs (interferons and glatiramer) have the lowest efficacy. It is less certain how these efficacy differences translate in the "real world," where the populations and related treatment decisions differ from the scenarios in trials. (See <a class="local">'Comparative efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing the risk of MS worsening</strong> – Clinicians should assess patients with RRMS at presentation and periodically thereafter for features associated with a poor prognosis and higher risk of future relapse and severe disability. The most important factors predicting a worse clinical course and poor long-term outcome are the presence of highly active disease (eg, frequent relapses and new MRI lesions), extensive radiologic involvement of MS lesions (eg, multifocal lesions, high lesion number; and high T2 burden of disease), and/or poor relapse recovery. (See <a class="local">'Assessment for risk of MS worsening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient- and drug-specific factors influencing DMT choice</strong> – Several issues may narrow DMT options, including patient values and preferences and drug-specific factors. Women of childbearing potential may wish to avoid some or all DMTs with the potential for fetal harm. (See <a class="local">'Factors influencing the choice of DMT'</a> above and  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a> and  <a class="medical medical_review" href="/z/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shared decision-making</strong> – Using shared decision making, the patient, clinician, and care team should jointly consider the decision to start a DMT and select the best option, evaluating the evidence of benefits, risks, and burdens of the available DMTs. (See <a class="local">'Shared decision-making'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment paradigms</strong> – There is no uniform method for selecting initial DMT for patients with RRMS. Two broad treatment paradigms are advocated by different experts: starting with highly effective therapy or starting with low-risk therapy. In addition, some experts and patients prefer to start with oral therapy, which is intermediate for efficacy and risk. (See <a class="local">'Selecting initial DMT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – For patients with RRMS, we recommend DMT (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We typically start with one of the agents listed below (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher effectiveness DMTs for initial treatment</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Intravenous <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a></p><p class="bulletIndent3"><span class="glyph">-</span>Intravenous <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a></p><p class="bulletIndent3"><span class="glyph">-</span>Subcutaneous <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermediate effectiveness DMTs for initial treatment</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Fumarates: oral <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, or <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a></p><p class="bulletIndent3"><span class="glyph">-</span>S1PR modulators: oral <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, or <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower effectiveness DMTs for initial treatment</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Oral <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a></p><p class="bulletIndent3"><span class="glyph">-</span>Intramuscular <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent3"><span class="glyph">-</span>Subcutaneous <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent3"><span class="glyph">-</span>Subcutaneous pegylated <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a></p><p class="bulletIndent3"><span class="glyph">-</span>Subcutaneous <a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">recombinant human interferon beta-1b</a></p><p class="bulletIndent3"><span class="glyph">-</span>Subcutaneous <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choosing among the DMT effectiveness categories</strong> – In choosing among these and other available DMTs, clinicians should incorporate individual patient prognostic factors, values and preferences, and drug-related factors (adverse effect profile, cost, availability, and burden of administration), using a shared decision making (see <a class="local">'Shared decision-making'</a> above) to optimize choices for individual patients  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). The following options are reasonable guides to selecting therapy (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with highly active disease, and for patients who place a high value on efficacy and are relatively risk-tolerant, start with highly effective therapy using intravenous <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> or <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with less active disease and for patients who value convenience using a self-administered medication compared with medications requiring injections or infusions, start with an oral fumarate or S1PR modulator.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who place the highest value on safety and have less active disease, start with one of the beta interferons or glatiramer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – The response to DMT can be monitored by clinical follow-up with careful attention to possible manifestations of MS disease activity including acute attacks (relapses), new or contrast-enhancing lesions on MRI, and, possibly, the onset or progression of sustained disability. (See <a class="local">'Monitoring response to therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777.</a></li><li><a class="nounderline abstract_t">Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24:96.</a></li><li><a class="nounderline abstract_t">Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci 2020; 47:437.</a></li><li><a class="nounderline abstract_t">Capra R, Cordioli C, Rasia S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler 2017; :1352458516687402.</a></li><li><a class="nounderline abstract_t">Lizak N, Lugaresi A, Alroughani R, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 2017; 88:196.</a></li><li><a class="nounderline abstract_t">Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 2019; 321:175.</a></li><li><a class="nounderline abstract_t">Palace J, Duddy M, Lawton M, et al. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry 2019; 90:251.</a></li><li><a class="nounderline abstract_t">Beiki O, Frumento P, Bottai M, et al. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. JAMA Neurol 2019; 76:665.</a></li><li><a class="nounderline abstract_t">Chalmer TA, Baggesen LM, Nørgaard M, et al. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 2018; 25:1262.</a></li><li><a class="nounderline abstract_t">Cobo-Calvo A, Tur C, Otero-Romero S, et al. Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event. Neurology 2023; 101:e1280.</a></li><li><a class="nounderline abstract_t">Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol 2019; 76:536.</a></li><li><a class="nounderline abstract_t">He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020; 19:307.</a></li><li><a class="nounderline abstract_t">Metz LM. Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. Continuum (Minneap Minn) 2019; 25:670.</a></li><li><a class="nounderline abstract_t">Amato MP, Fonderico M, Portaccio E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 2020; 143:3013.</a></li><li><a class="nounderline abstract_t">Claflin SB, Broadley S, Taylor BV. The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses. Front Neurol 2018; 9:1150.</a></li><li><a class="nounderline abstract_t">Tsivgoulis G, Katsanos AH, Grigoriadis N, et al. The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS One 2015; 10:e0144538.</a></li><li><a class="nounderline abstract_t">Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology 2021; 96:e783.</a></li><li><a class="nounderline abstract_t">Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2015; :CD011381.</a></li><li><a class="nounderline abstract_t">Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol 2017; 16:271.</a></li><li><a class="nounderline abstract_t">Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376:221.</a></li><li><a class="nounderline abstract_t">Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn) 2019; 25:715.</a></li><li><a class="nounderline abstract_t">Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014; 20:705.</a></li><li><a class="nounderline abstract_t">Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911.</a></li><li><a class="nounderline abstract_t">Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819.</a></li><li><a class="nounderline abstract_t">Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829.</a></li><li><a class="nounderline abstract_t">Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402.</a></li><li><a class="nounderline abstract_t">Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.</a></li><li><a class="nounderline abstract_t">Fogarty E, Schmitz S, Tubridy N, et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord 2016; 9:23.</a></li><li><a class="nounderline abstract_t">Signori A, Saccà F, Lanzillo R, et al. Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm 2020; 7.</a></li><li><a class="nounderline abstract_t">Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021; 78:558.</a></li><li><a class="nounderline abstract_t">Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol 2019; 26:27.</a></li><li><a class="nounderline abstract_t">McKay KA, Jahanfar S, Duggan T, et al. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology 2017; 61:189.</a></li><li><a class="nounderline abstract_t">Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138:1863.</a></li><li><a class="nounderline abstract_t">Mowry EM, Pesic M, Grimes B, et al. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009; 256:1061.</a></li><li><a class="nounderline abstract_t">Louapre C, Bodini B, Lubetzki C, et al. Imaging markers of multiple sclerosis prognosis. Curr Opin Neurol 2017; 30:231.</a></li><li><a class="nounderline abstract_t">Rahn AC, Köpke S, Stellmann JP, et al. Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review. Acta Neurol Scand 2019; 139:18.</a></li><li><a class="nounderline abstract_t">Briggs FBS, Thompson NR, Conway DS. Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 2019; 30:9.</a></li><li><a class="nounderline abstract_t">Iacobaeus E, Arrambide G, Amato MP, et al. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Mult Scler 2020; :1352458520925369.</a></li><li><a class="nounderline abstract_t">Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler 2017; 23:185.</a></li><li><a class="nounderline abstract_t">Solari A, Martinelli V, Trojano M, et al. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler 2010; 16:1393.</a></li><li><a class="nounderline abstract_t">Ben-Zacharia A, Adamson M, Boyd A, et al. Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis. Int J MS Care 2018; 20:287.</a></li><li><a class="nounderline abstract_t">Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007; 256 Suppl 1:S5.</a></li><li><a class="nounderline abstract_t">Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol 2021; 78:1197.</a></li><li><a class="nounderline abstract_t">Metin H, Huppertz H. Adjusted Indirect Comparison of Oral Multiple Sclerosis Agents. Value Health 2015; 18:A750.</a></li><li><a class="nounderline abstract_t">Fox RJ, Cutter G, Chan A, et al. Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis. Value Health 2015; 18:A750.</a></li><li><a class="nounderline abstract_t">Thomas RH, Wakefield RA. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Am J Health Syst Pharm 2015; 72:25.</a></li><li><a class="nounderline abstract_t">Wijburg MT, Warnke C, McGuigan C, et al. Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. J Neurol Neurosurg Psychiatry 2021; 92:177.</a></li><li><a class="nounderline abstract_t">Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021; 20:653.</a></li><li><a class="nounderline abstract_t">Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology 2015; 276:228.</a></li><li><a class="nounderline abstract_t">McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 2015; 275:772.</a></li><li><a class="nounderline abstract_t">Kanda T, Nakai Y, Oba H, et al. Gadolinium deposition in the brain. Magn Reson Imaging 2016; 34:1346.</a></li><li><a class="nounderline abstract_t">Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR. Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 2016; 34:1359.</a></li><li><a class="nounderline abstract_t">Traboulsee A, Li D. Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2016; 37:E82.</a></li></ol></div><div id="topicVersionRevision">Topic 1687 Version 115.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686116" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29353550" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654681" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28080255" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27683916" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30644981" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30242090" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882868" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29847005" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early versus later treatment start in multiple sclerosis: a register-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37468284" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776055" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199096" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162311" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32935843" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687214" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642051" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33372028" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384035" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209331" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002679" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162313" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126064" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510745" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122652" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122650" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089954" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992072" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27645339" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801167" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cladribine vs other drugs in MS: Merging randomized trial with real-life data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779698" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30300457" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multiple sclerosis - a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27045883" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25902415" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Defining high, medium and low impact prognostic factors for developing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252775" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical predictors of early second event in patients with clinically isolated syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362719" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Imaging markers of multiple sclerosis prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091223" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711764" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognostic factors of disability in relapsing remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32530385" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Aggressive multiple sclerosis (1): Towards a definition of the phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27663871" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Shared decision-making in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858692" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30568566" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346747" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The natural history of relapses in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398221" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26534200" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adjusted Indirect Comparison of Oral Multiple Sclerosis Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26534203" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33229453" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34139157" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25942417" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742194" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613998" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gadolinium deposition in the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27720805" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gadolinium tissue deposition in brain and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27585702" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
